Arjun Nathan

⭐ Thrilled to see @COMPASSurology research cited in the #EAU26 PCa Guidelines! 📍 GLIMPSE (@radiology_rsna): Highlighting the global variation and feasibility of quality improvement 📍 PRIME (@JAMA_current): Confirming non-inferiority of bpMRI to mpMRI for csPCa detection

📣 𝐍𝐄𝐖𝐒 𝐅𝐋𝐀𝐒𝐇 - #WASHOUT 𝐇𝐀𝐒 𝐆𝐎𝐍𝐄 𝐕𝐈𝐑𝐀𝐋 🌍 We are incredibly proud and grateful that our latest flagship study has been featured by media outlets across the globe! 🔍 𝐊𝐞𝐲 𝐟𝐢𝐧𝐝𝐢𝐧𝐠𝐬: 🩸 ~25% of patients presenting with emergency haematuria had an underlying cancer 🚨 Mortality rate of almost 10% 🩻 Patients who did not receive investigations or appropriate treatment were 2.5× more likely to die within three months. 
⏱️ Investigation within 48h reduced length of stay, readmissions and mortality ⌛️ No investigations or treatment in the first 48 hours increases length of stay by 5.6 days, mortality by 2.6% and readmission risk by 3.6%
 🔑 𝐓𝐡𝐞 𝐦𝐞𝐬𝐬𝐚𝐠𝐞 𝐢𝐬 𝐜𝐥𝐞𝐚𝐫: Visible haematuria should not be ignored. Rapid investigation is key for patients presenting with emergency haematuria with high rates of underlying malignancy. 📰 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐚𝐫𝐭𝐢𝐜𝐥𝐞𝐬: 🇬🇧 The Sun
lnkd.in/eNXxhUcc 🇬🇧 The Telegraph
lnkd.in/e8aFwJua 🇮🇪 Irish Independent lnkd.in/e4s-AADP 🇪🇸 La Razón
lnkd.in/e8fjz88J 🇪🇸 El Debate
lnkd.in/esSp3ZKZ 🇪🇸 El Diario
lnkd.in/eXxXXazt 🇬🇧🇦🇺 News Medical
lnkd.in/eQnsfUh7 🎥 Watch the full European Association of Urology TV interview with Co-Chief Investigator @NikitaB0709 - lnkd.in/eDV9eKuJ 👀 Full results coming very soon - watch this space! A huge thank you to our collaborators behind #WASHOUT. We're also grateful to our funders for their support: @TUF_tweets Charles Reynolds Foundation @Actionbladderca and @RosetreesT @NikitaB0709 @kgbyrnes @QuentinMak @BingjieChow @NikkiKerdegari @ippoliti_simona @AlexBCDNg @AquaAsif @ArjunSNathan @benchallacombe @veerukasi

🔥 𝐇𝐨𝐭 𝐨𝐟𝐟 𝐭𝐡𝐞 𝐩𝐫𝐞𝐬𝐬 -#WASHOUT featured in @Telegraph 🩸WASHOUT is the largest study to date investigating the management of emergency haematuria with 8,500+ patients across >350 hospitals globally 🔍 𝐖𝐡𝐚𝐭 𝐰𝐞 𝐟𝐨𝐮𝐧𝐝: 🩻 Patients who did not receive investigations or appropriate treatment were 2.5× more likely to die within three months. 🧬 Approximately one quarter of patients were found to have an underlying cancer. ⏰ For patients with underlying cancer, those having investigations within 48 hours received a diagnosis within one day on average, compared with ~3 weeks for those discharged without investigation. 🏥 Lack of investigation is associated with longer hospital stays. ❓𝐖𝐡𝐲 𝐭𝐡𝐢𝐬 𝐦𝐚𝐭𝐭𝐞𝐫𝐬: Emergency haematuria is a prevalent urological emergency accounting for at least 15% of all urological emergency admissions in the UK and 10% readmitted within 30 days. Despite this, there are no standardised guidelines for management. 
 🔑 Prompt investigation is crucial for timely diagnosis and treatment. 𝐅𝐢𝐧𝐝 𝐨𝐮𝐭 𝐦𝐨𝐫𝐞: 🔗 Check out the full article: lnkd.in/e8aFwJua 🎥 Watch the full interview, featuring our Co-Chief Investigator, @NikitaB0709, on @Uroweb EAU TV lnkd.in/eDV9eKuJ 👀 Full results will be out very soon - watch this space! Thank you for all our sites and collaborators! Thank you to our founders @TUF_tweets & Charles Reynolds Foundation, @Actionbladderca, and @RosetreesT @NikitaB0709 @kgbyrnes @kmj_gallagher @QuentinMak @BingjieChow @NikkiKerdegari @ippoliti_simona @AlexBCDNg @AquaAsif @ArjunSNathan @benchallacombe @veerukasi 📄 telegraph.co.uk/news/2026/03/1…

1/ 📢 PUBLICATION ALERT! #RESECT is one of @BURSTurology’s most ambitious studies, with a novel #trial design - a cluster RCT with 200+ sites with 15000+ patients, now in @EUplatinum ⚡ Can private, personal feedback and education about endoscopic surgery (TURBT) change surgeon behaviour and improve outcomes in bladder cancer? 🤔 Read HERE: doi.org/10.1016/j.euru…

BURST at #EAU26 | The Future of International Research 📅 Sat 14 Mar | 🕐 13:00-15:00 | 📍 Connaught 1 ✅ #WASHOUT results & next steps 🌍 Global collaborator perspectives on international research 🚀 Open discussion: how to get involved with BURST See you in London! #UroSoMe

We are proud to announce that BURST and @ManchesterAndro are bringing UK experts together to reach #consensus for the investigation, management and follow-up of priapism. Let's bring #CLARITY

📢 TUF x BURST: X-Factor is back for #BAUS26! Got an idea (no prior research experience needed) & think it could change practice? 🏆 2 prizes (Overall Winner + People’s Choice) 💰 Share of £1000 🤑 ⏰ NEW Deadline: 23:59, 12 Feb #UroSoMe Submit HERE: forms.gle/NpC5ayznq5TeaR…

Hear from PPI Partner, Derek Shep on the #ELIPSE Trial and why clear, patient-led information is important in prostate cancer research. 🔬

🔥TUF X BURST: X-Factor returns for #BAUS26 - this time bigger and better! Got a QIP, audit or innovation idea? Submit it for a chance to have it refined, present at BAUS 26 and a shot at a share of £1,000! ⌛Deadline: 1st Feb 2026 🔗Link: forms.gle/NpC5ayznq5TeaR… #UROSoMe

Excited to announce that we have partnered with the #PARTIAL team to help answer the question of partial vs radical #nephrectomy for localised #RCC 🔍 #UroSoMe

📢 Meet some of our new ELIPSE–BURST Associate PIs! Interested in joining the network? 👩‍⚕️👨‍⚕️ Contact @BURSTUrology to find out more!

🤔 Got a question about the use of systemic anti-cancer treatment in metastatic prostate cancer? The @NPCA_uk is here to help! Submit your questions and our expert panel will answer them in our webinar on 23 Oct 9am👉 forms.gle/hzbAQwez2yAtSN…  🔗 NPCAxBURST.eventbrite.com

👇The programme for our webinar with @NPCA_uk on the use of systemic anti-cancer treatment in metastatic prostate cancer on 23 Oct 9am 🧬Evidence for use of ARPIs 💊Safe prescribing 🫀CV and bone health- mitigating effects of ADT ±ARPIs 🔎Case studies  🔗NPCAxBURST.eventbrite.com

🚀 We are delighted to announce our upcoming webinar with @NPCA_uk - “The use of systemic anti-cancer treatment in metastatic prostate cancer.”  🗓️ Join us on 23rd Oct for an evidence-based update on systemic therapy in metastatic prostate cancer 🔗 NPCAxBURST.eventbrite.com

🆕 Great to see #PRIME published - an effective and efficient trial to determine a new standard of practice 👏 What you won’t see published is the amount of hard work carried out behind the scenes to deliver this work @veerukasi @AlexBCDNg @AquaAsif Read 👇

❗Exciting news from @BURSTurology! 🤝 We’re proud to announce our partnership with the ELIPSE clinical trial team 🥇 This collaboration is a first for BURST, and embodies BURST’s mission of empowering the next generation of urologists.

Recruitment milestones so far: ✅ 300+ sites worldwide ✅ 8,500+ patients entered 🗓️ Final 3-month follow-up deadline: Dec 2025 📝 Main paper expected late 2026 ✨ A huge thank you to every collaborator driving #WASHOUT forward. #UroSoMe #Haematuria

📢 PUBLICATION ALERT The #WASHOUT protocol is out 🥳 🤔 #Haematuria = ~15% of emergency urology admissions with ⏫ variation in practice & resource use 🥇This is the FIRST international study to map how haematuria is managed globally 🤯 🔗 doi.org/10.1136/bmjope… #UroSoMe

@JoannaDodkins @NPCA_uk @NATCAN_news @ProstateUK Congratulations Jo! Great to see your great work getting the dissemination it deserves

Proud moment – my PhD research has made the front page of The Telegraph today! I’m grateful to be part of such impactful work with the National Prostate Cancer Audit (NPCA) team within the National Cancer Audit Collaborating Centre (NATCAN) @NPCA_uk @NATCAN_news @ProstateUK

Still buzzing after #BAUS25 @BAUSurology! ✨ BURST packed out 3️⃣ sessions, from the Research X Factor pitches to our decade-of-trials celebration, and kept the room talking #evidence all the way. Missed it? Catch the write-up in @Uro_News👇 urologynews.uk.com/news/post/burs… #UroSoMe